Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
June 15 2021 - 9:51AM
Dow Jones News
By Chris Wack
Jounce Therapeutics Inc. said the U.S. Food and Drug
Administration has cleared its investigational new drug application
for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences Inc.
has exclusive rights to develop and commercialize.
The IND clearance triggers a $25 million milestone payment to
Jounce.
Jounce said JTX-1811, which will be referred to as GS-1811 in
Gilead's pipeline, is a monoclonal antibody created by Jounce and
designed to selectively deplete immunosuppressive
tumor-infiltrating T regulatory cells. The target of JTX-1811 is
CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811
binds to CCR8, it targets TITR cells for depletion by enhancing an
antibody-dependent cellular cytotoxicity mechanism.
Under the terms of their September 2020 agreement, Gilead
invested $35 million in Jounce's common stock and made an $85
million upfront payment to Jounce. Jounce has led the development
of JTX-1811 through IND clearance, after which Gilead now has the
sole right to develop and commercialize the program.
After receiving the $25 million milestone payment, Jounce may
receive up to an additional $660 million in future clinical,
regulatory and commercial milestone payments and will also be
eligible to receive royalties ranging from high single digit to
mid-teens based upon worldwide sales.
Jounce shares were up 9% to $7.60 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 15, 2021 09:36 ET (13:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024